N-1-丙基苯并三唑 | 16584-02-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: N-1-丙基苯并三唑
• 英文名称: 1-propyl-1H-benzotriazole
• 英文别名: N-1-propylbenzotriazole；1-n-Propylbenzotriazol；1-propylbenzotriazole；1-propyl-1H-benzotriazole；1-Propyl-1H-benzotriazol；1-Propyl-1H-1,2,3-benzotriazole
• CAS: 16584-02-4
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: KMHKYOIGRHFJBP-UHFFFAOYSA-N

物化性质

• 熔点：
  32-33 °C
• 沸点：
  292.7±9.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-1-丙基苯并三唑 在 二甲基二环氧乙烷 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以76%的产率得到3-propyl-3H-1,2,3-benzotrizole 1-oxide
  参考文献：
  名称：

  Conversions by Dimethyldioxirane of 1-Alkylbenzotriazoles into Their N-Oxides and of 2-Alkylbenzotriazoles into 2-Alkyl-trans-4,5,6,7-diepoxy-4,5,6,7-tetrahydrobenzotriazoles

  摘要：

  Dimethyldioxirane converted 1-alkylbenzotriazoles 4 to the corresponding 3-alkylbenzotriazole 1-oxides 5 in good yields, but transformed 2-alkylbenzotriazoles 12 into 2-alkyl-trans-4,5,6,7-diepoxy-4,5,6,7-tetrahydrobenzotriazoles 13.

  DOI：

  10.1021/jo010194g
• 作为产物：
  描述：

  1-(氯甲基)-1H-苯并三唑 以 甲醇 、 乙醚 、 甲苯 、 苯 为溶剂， 反应 2.0h， 生成 N-1-丙基苯并三唑
  参考文献：
  名称：

  Reactions of 1-(.alpha.-alkoxyalkyl)- and 1-(.alpha.-(aryloxy)alkyl)benzotriazoles with the Grignard reagents. A new and versatile method for the preparation of ethers

  摘要：

  DOI：

  10.1021/jo00287a011

文献信息

• [EN] ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE ALPHA-AMINO BORONIQUE, INHIBITEURS SÉLECTIFS DE L'IMMUNOPROTÉASOME
  申请人：ARES TRADING SA

  公开号：WO2013092979A1

  公开（公告）日：2013-06-27

  The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases. In formula (I), Rb and Rc are independently selected from one another from H or C1-C6-alkyl; whereby Rb and Rc may be linked to form a 5 or 6 membered-ring containing the oxygen atoms to which they are linked; Q denotes Ar, Het or cycloalkyl; R1 R2 independently from each other denotes H, ORa, Hal, C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; Y denotes CR 3R4, preferably CH2 or C(CH3)2; R 3, R4 independently of one another denote H or C1-C6-alkyl; L denotes L1 or L2 or alkyl; n is an integer selected from 0 to 3; L 1 is Q1-CO-M- wherein Q 1 is Ar or Het, preferably, phenyl, naphthyl or pyridine, optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; L2 is Q2-M- wherein Q 2 is a fused bicyclic system containing 1 nitrogen atom and 1 to 3 additional groups independently selected from O, S, N, or CO, and wherein at least one of the rings is aromatic whereby the fused bicyclic system is optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; or Q 2 is unsaturated or aromatic 5 membered-ring system containing 1 to 3 heteroatoms selected from N, O, S and CO, and optionally substituted with a phenyl ring or pyridine ring whereby phenyl ring and pyridine ring are optionally substituted with 1 to 4 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; M is a linear or branched alkylene having 1 to 5 carbon atoms wherein 1 or 2 H atoms may be replaced by OR a or a phenyl ring optionally substituted with 1 to 5 groups independently selected from Hal, ORa, and C1-C6-alkyl optionally substituted with 1 to 5 groups independently selected from OH, and Hal; or M denotes a cycloalkylene having 3 to 7 carbon atoms; or M denotes a thiazolidinyl group; R a is H or C1-C6-alkyl wherein 1 to 5 H atom may be independently replaced by OH or Hal; Ar denotes a 6 membered-aromatic carbocyclic ring optionally fused with another carbocyclic saturated, unsaturated or aromatic ring having 5 to 8 carbon atoms; Het denotes a 5- or 6-membered saturated, unsaturated or aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from N, N+O-, O, S, SO, and SO 2, and optionally fused with another saturated, unsaturated or aromatic ring having 5 to 8 atoms and optionally containing 1 to 3 heteroatoms selected from N, O, and S; Hal denotes CI, Br, I of F; preferably CI or F.

  本发明提供了化合物的公式（I）作为LMP7的抑制剂，用于治疗自身免疫和炎症性疾病。在公式（I）中，Rb和Rc分别独立地从H或C1-C6-烷基中选择；其中Rb和Rc可以连接形成一个含有它们连接的氧原子的5或6元环；Q表示Ar，Het或环烷基；R1和R2彼此独立地表示H，ORa，Hal，C1-C6-烷基，其中1到5个H原子可以独立地被OH或Hal替换；Y表示CR 3R4，优选CH2或C(CH3)2；R3，R4彼此独立地表示H或C1-C6-烷基；L表示L1或L2或烷基；n是从0到3选择的整数；L1是Q1-CO-M-，其中Q1是Ar或Het，优选苯基，萘基或吡啶基，可选地取代为1到5个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；L2是Q2-M-，其中Q2是含有1个氮原子和1到3个额外基团的融合双环系统，独立选择自O，S，N或CO，其中至少一个环是芳香环，融合双环系统可选地取代为1到5个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；或Q2是不饱和或芳香的含有1到3个从N，O，S和CO中选择的杂原子的5元环系统，并可选地取代为苯环或吡啶环，其中苯环和吡啶环可选地取代为1到4个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；M是具有1到5个碳原子的线性或支链烷基，其中1或2个H原子可以被ORa或可选地取代为1到5个从Hal，ORa和C1-C6-烷基中独立选择的基团，可选地取代为1到5个从OH和Hal中独立选择的基团；或M表示具有3到7个碳原子的环烷基；或M表示噻唑烷基；Ra是H或C1-C6-烷基，其中1到5个H原子可以独立地被OH或Hal替换；Ar表示一个6元芳香碳环，可选地与另一个含有5到8个碳原子的碳环饱和、不饱和或芳香环融合；Het表示一个含有1到3个从N，N+O-，O，S，SO和SO2中独立选择的杂原子的5或6元饱和、不饱和或芳香杂环，可选地与另一个含有5到8个原子的饱和、不饱和或芳香环融合，并可选地含有1到3个从N，O和S中选择的杂原子；Hal表示CI，Br，I或F；优选CI或F。
• Aqueous Micellar Medium in Organic Synthesis: Alkylations and Michael Reactions of Benzotriazole
  作者：Sabir Hussain Mashraqui、Sukeerthi Kumar、Chandrasekhar Dayal Mudaliar

  DOI：10.1246/bcsj.74.2133

  日期：2001.11

  cetyltrimethylammonium bromide in catalyzing C–N bond formation has been studied with respect to N-alkylations of benzotriazole (Bt). Alkylations with various alkylating agents and the addition of Bt across activated double bonds in the Michael fashion occurred successfully in fair-to-good yields in the aqueous micellar regime. These reactions provided a mixture of N-1 and N-2 alkylated products, with a marked preference

  关于苯并三唑 (Bt) 的 N-烷基化，研究了十六烷基三甲基溴化铵水胶束催化 C-N 键形成的可行性。在水性胶束体系中，用各种烷化剂烷基化和以迈克尔方式在活化的双键上添加 Bt 成功地发生了从公平到良好的产率。这些反应提供了 N-1 和 N-2 烷基化产物的混合物，N-1 异构体明显优于 N-2 异构体。已通过实验评估胶束催化，表明与它们的水性对应物相比，对这些烷基化的胶束贡献超过 50%。由于 N-烷基苯并三唑具有潜在的生物学意义，因此本胶束程序为其他可用方法提供了方便的替代方法。
• [EN] NEW QUATERNARY AMMONIUM SALTS, METHOD FOR PREPARATION AND APPLICATIONS THEREOF<br/>[FR] NOUVEAUX SELS D'AMMONIUM QUATERNAIRE, LEUR PROCÉDÉ DE PRÉPARATION ET LEURS APPLICATIONS
  申请人：UNIV MEDYCZNY IM KAROLA MARCINKOWSKIEGO

  公开号：WO2013115661A1

  公开（公告）日：2013-08-08

  The invention relates to a novel class of quaternary ammonium salts containing tetra-hydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium moiety in the structure, in particular the new derivatives of 4-methyltetrahydro[1,3]oxazolo[2,3-b] [1,3]oxazol-4-ium, 4-(2-oxoethyl)tetrahydro-[1,3]oxazolo[2,3-6][1,3]oxazol-4-ium, bis4-methyltetrahydro[1,3]oxazoio[2,3-6][1,3]oxazol-4-ium}, bis4-(2-oxoethyl)tetrahydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium} and tris4-methyl-tetrahydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium} salts, process for the preparation of a novel class of quaternary ammonium salts and applications thereof.

  该发明涉及一种新型的季铵盐类，其结构中含有四氢[1,3]噁唑啉[2,3-b][1,3]噁唑-4-ium基团，特别是4-甲基四氢[1,3]噁唑啉[2,3-b][1,3]噁唑-4-ium的新衍生物，4-(2-氧乙基)四氢-[1,3]噁唑啉[2,3-6][1,3]噁唑-4-ium，双4-甲基四氢[1,3]噁唑啉[2,3-6][1,3]噁唑-4-ium}，双4-(2-氧乙基)四氢[1,3]噁唑啉[2,3-b][1,3]噁唑-4-ium}和三4-甲基-四氢[1,3]噁唑啉[2,3-b][1,3]噁唑-4-ium}盐，以及一种制备新型季铵盐类和其应用的方法。
• QUATERNARY AMMONIUM SALTS, METHOD FOR PREPARATION AND APPLICATIONS THEREOF
  申请人：UNIWERSYTET MEDYCZNY IM. KAROLA MARCINKOWSKIEGO

  公开号：US20150080583A1

  公开（公告）日：2015-03-19

  The invention relates to a novel class of quaternary ammonium salts containing tetra-hydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium moiety in the structure, in particular the new derivatives of 4-methyltetrahydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium, 4-(2-oxoethyl)tetrahydro[1,3]oxazolo[2,3-6][1,3]oxazol-4-ium, bis4-methyltetrahydro[1,3]oxazoio[2,3-6][1,3]oxazol-4-ium}, bis4-(2-oxoethyl)tetrahydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium} and tris4-methyltetrahydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium} salts, process for the preparation of a novel class of quaternary ammonium salts and applications thereof.

  该发明涉及一类新型的季铵盐，其结构中含有四氢[1,3]噁唑啉[2,3-b][1,3]噁唑-4-ium基团，特别是4-甲基四氢[1,3]噁唑啉[2,3-b][1,3]噁唑-4-ium的新衍生物，4-(2-氧乙基)四氢[1,3]噁唑啉[2,3-6][1,3]噁唑-4-ium，双4-甲基四氢[1,3]噁唑啉[2,3-6][1,3]噁唑-4-ium}，双4-(2-氧乙基)四氢[1,3]噁唑啉[2,3-b][1,3]噁唑-4-ium}和三4-甲基四氢[1,3]噁唑啉[2,3-b][1,3]噁唑-4-ium}盐，以及一种制备新型季铵盐类的方法和应用。
• [EN] METHODS FOR TREATING NEURON DAMAGE<br/>[FR] MÉTHODES DE TRAITEMENT DE LÉSIONS NEURONALES
  申请人：COYOTE PHARMACEUTICALS INC

  公开号：WO2014107686A1

  公开（公告）日：2014-07-10

  This invention relates to the use of geranylgeranyl acetone (GGA), its isomers, and GGA derivatives in a method for for treating a disease in a subject mediated in part by miRNA-378 or miRNA-711 increased activity comprising administering to the subject a therapeutically effective amount of 5-trans-GGA or a derivative thereof.

  本发明涉及在治疗由miRNA-378或miRNA-711增强活性部分介导的主体疾病的方法中使用生育醇醇丙酮（GGA）、其异构体和GGA衍生物，包括向主体施用治疗有效量的5-反式-GGA或其衍生物。